This site is intended for healthcare professionals
News

Health Canada approves Arazlo lotion, 0.045%

Read time: 1 mins
Published:6th Aug 2021
Bausch Health,Canada, which is part of Bausch Health Companies Inc. and its dermatology division, one of the largest prescription dermatology health care businesses in Canada, announced that Health Canada has approved the Notice of Compliance (NOC) for Arazlo (tazarotene) lotion, 0.045%, for the topical treatment of acne vulgaris (common acne) in patients 10 years of age and older.

Arazlo is the first tazarotene acne treatment available in a lotion formulated with Prismatrex technology (a formulation with known hydrating and moisturizers, which may alleviate dryness of skin) and has been shown to provide strong efficacy with a good tolerability profile. Retinoids like tazarotene are a core component of acne treatment.

Condition: Acne
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.